A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of non-squamous NSCLC withevidence of KRAS G12C mutation via tumor sample and/or circulating tumordeoxyribonucleic acid (ctDNA).

• Locally advanced or metastatic disease.

• Measurable disease via computed tomography (CT) or magnetic resonance imaging (MRI)per RECIST v1.1 criteria of at least 1 lesion.

• No prior systemic anti-cancer therapy given for advanced or metastatic disease.

• Not a candidate for definitive therapy (eg, chemoradiation or complete surgicalresection).

• Participants with brain metastases are eligible for enrollment, including those withuntreated brain metastases. Brain metastases must be asymptomatic and not in need ofimmediate local therapy. Any untreated brain metastases must be ≤ 20 mm in diameter.

• Any PD-L1 expression (0 to 100%) as determined by VENTANA PD-L1 (SP263) assay,Agilent PD-L1 IHC 22C3 pharmDx, or Agilent PD-L1 IHC 28-8 pharmDx.

Exclusion Criteria:

• Participants with an active autoimmune or inflammatory disease requiring systemictreatment within 2 years.

• Uncontrolled or significant cardiovascular conditions within 6 months prior toenrollment that are ongoing or with risk of recurrence.

• Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities.

• Ongoing treatment with concomitant medication known to cause prolonged QTc intervaland that cannot be switched to alternative treatment prior to study entry.

• Treatment targeting KRAS G12C mutation (eg, sotorasib, adagrasib) in any setting.

• Other severe acute or chronic medical or psychiatric condition or laboratoryabnormality that may increase the risk associated with study participation or studydrug administration.

• Other protocol-defined Inclusion/Exclusion criteria apply.